

ABSTRACT

Annual Meeting Symposia

AS1-1 Introduction : promotion of open innovation for drug innovation

Akinori Akaike^{1,2}

¹Dept. Cell. Pharmacol., Grad. Sch. Pharm. Sci., Nagoya Univ., ²Dept. Pharmacol., Grad. Sch. Pharm. Sci., Kyoto Univ.

Drug innovation aiming to solutions for unmet medical needs is one of the most important issues in Japan reaching a highly aging society. Exchange of ideas between researchers across walls of organizations will contribute to the achievement of the discovery of the new type of drugs. It is widely recognized that the promotion of open innovation for drug innovation provides a platform for idea-sharing and lowers the barrier for collaborations among researchers in basic and clinical fields in universities and drug industries. The participation of government officers in regulatory science is also important in accelerating the achievement of the drug innovation. In this symposium, 5 speakers will present the situation of the open innovation drug discovery and regenerative medicine of Japan and USA. Latter part of my presentation will be focused on the activity of Consortium for Drug Innovation in the Tokai Region (CDIT) as an example of the pipeline construction between universities and drug industries. The activity of CDIT focuses in the matching of the needs of the drug industries and research results of the universities. Those activities will greatly support the development of innovative drugs and medicine.

AS1-3 Current status and issues of pharmaceutical development in Japan: Toward healthy social security finances and pharmaceutical industry growth

Yoshihide Esaki

Director Bio-industry Division, Ministry of Economy, Trade and Industry

Advances in regulatory science are increasingly causing difficulties for the development of new drugs, not only in Japan but globally. These changes in the environment for drug discovery, however, have also provided Japanese pharmaceutical companies, which have previously lagged behind in the race to develop antibody drugs and other bio-medicines, with a chance to catch up. Promotion of personalized medicine will be the key, and to achieve this will require not only the transformation of the business models used by pharmaceutical companies but also the review of the approval process for new drugs. Such initiatives will both give Japan the advantage in the clinical trial environment, where the high costs caused by rigorous quality control are recognized to be issue currently, and make it easier for pharmaceutical companies to approach academic startups, and may also help to promote open innovation in Japan.

AS1-2 Trend on open innovation for drug discovery research

Yayoi Sasaki

Japan Health Sciences Foundation

Japan Health Sciences Foundation(JHSF) is advancing research and survey project on various topics relating to drug discovery research based on advanced and basic sciences and technology, the medical needs, the future trends of the disease and medical treatment, etc., since 1986 of JHSF establishment. The overseas survey report which is investigating the drug discovery strategy and technology of overseas pharmaceutical companies introduced outsourcing in various stages of drug discovery several years before. After the open innovation was advocated, about ten years have passed. The measure in the national pharmaceutical companies recently followed the open innovation as outsourcing of search of drug discovery. The trend in and outside the country was adjusted in the report 'Open innovation for drug discovery - use of the research resource by external cooperation-', research resource committee's report in the 2012 fiscal year. At this symposium, the trend on open innovation for drug discovery would be summarized.

AS1-4 Acceleration of open innovation from the standpoint of start-up company

Naoki Tani

RaQualia Pharma Inc.

RaQualia Pharma Inc., a spinout from Pfizer Inc.'s Japan research operation, is a research and development-based pharmaceutical company in Aichi prefecture and began its operation in July 2008. At present, RaQualia's primary emphasis is on pain and gastrointestinal disease areas targeting ion channels. From the beginning of its operation, RaQualia firmly believes that innovation will be achieved via open collaboration with academia and private sectors. Our knowledge gained from broad experiences will enable implementation of a transcendent collaboration network that leaps industry barriers and serves as the driving force for effective and efficient research and development of new drugs. Against this background, we have made a strategic decision to relocate the discovery functions of the company to Nagoya University, expecting that further synergy effect with academia will be achieved. RaQualia and Nagoya University established a division of analytical study on efficacy pharmacology in February 2014. They will jointly work to identify innovative drug candidates, combining RaQualia's drug discovery expertise and Nagoya University's academic research capabilities. Open collaboration and trust are vital components to our strength and our business model.

Download English Version:

<https://daneshyari.com/en/article/2548946>

Download Persian Version:

<https://daneshyari.com/article/2548946>

[Daneshyari.com](https://daneshyari.com)